Want to see HK:1066 full AI Analyst Report?
1066 Stock Chart & Stats
HK$3.48
HK$0.03(0.92%)
At close: 4:00 PM EDT
HK$3.48
HK$0.03(0.92%)
Day’s Range― - ―
52-Week RangeHK$2.92 - HK$6.30
Previous CloseN/A
Volume6.46M
Average Volume (3M)11.75M
Market Cap
HK$14.79B
Enterprise ValueHK$11.81K
Total Cash (Recent Filing)HK$8.92B
Total Debt (Recent Filing)HK$4.96B
Price to Earnings (P/E)9.4
Beta1.10
Next Earnings
Mar 30, 2027EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend Yield5.31%
Share Statistics
EPS (TTM)0.30
Shares Outstanding4,522,332,500
10 Day Avg. Volume9,110,043
30 Day Avg. Volume11,746,737
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)0.85
Price to Sales (P/S)1.53
P/FCF Ratio11.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$4.54Price Target Upside30.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.33
Revenue Forecast (FY)HK$13.85B
Bulls Say, Bears Say
Bulls Say
Recurring Hospital Consumables DemandThe company serves routine clinical workflows with single-use products, creating repeat purchasing tied to hospital utilization and patient volumes. This consumables model can support durable demand and recurring revenue, while broader hospital procurement access may provide a foundation for ongoing sales.
Conservative Leverage And Stable CapitalizationModerate leverage reduces financial risk and preserves flexibility to fund operations, maintain products, and withstand periods of weaker profitability. The growing equity base also indicates stable capitalization, giving the company a stronger foundation than a highly debt-dependent medical-device business.
Positive Cash GenerationPositive operating and free cash flow indicates that the business continues to convert its operations into internally generated funds. That supports reinvestment, financial obligations, and shareholder returns without relying entirely on external financing, even though the latest trend has weakened.
Bears Say
Sharp 2025 Revenue ContractionThe sharp 2025 revenue decline signals a meaningful deterioration in demand, market execution, or product performance rather than sustained expansion. If the contraction persists, lower scale could weaken operating leverage, reduce reinvestment capacity, and make recovery in earnings more difficult.
Structural Margin CompressionMulti-year gross and net margin erosion shows that profitability has weakened across the business, reducing the earnings produced by each unit of revenue. Continued pressure could limit cash available for innovation and make results more sensitive to product mix, pricing, and operating costs.
Lower Returns On EquityThe decline in return on equity indicates that the company is generating less profit from its shareholder capital than it did previously. This weakens the efficiency of the business model and may constrain long-term value creation unless profitability, revenue scale, or asset productivity improves.
Shandong Weigao Group Medical Polymer Co News
1066 FAQ
What was Shandong Weigao Group Medical Polymer Co Ltd Class H’s price range in the past 12 months?
Shandong Weigao Group Medical Polymer Co Ltd Class H lowest stock price was HK$2.92 and its highest was HK$6.30 in the past 12 months.
What is Shandong Weigao Group Medical Polymer Co Ltd Class H’s market cap?
Shandong Weigao Group Medical Polymer Co Ltd Class H’s market cap is HK$14.79B.
When is Shandong Weigao Group Medical Polymer Co Ltd Class H’s upcoming earnings report date?
Shandong Weigao Group Medical Polymer Co Ltd Class H’s upcoming earnings report date is Mar 30, 2027 which is in 185 days.
How were Shandong Weigao Group Medical Polymer Co Ltd Class H’s earnings last quarter?
Shandong Weigao Group Medical Polymer Co Ltd Class H released its earnings results on Aug 25, 2026. The company reported HK$0.198 earnings per share for the quarter.
Is Shandong Weigao Group Medical Polymer Co Ltd Class H overvalued?
According to Wall Street analysts Shandong Weigao Group Medical Polymer Co Ltd Class H’s price is currently Undervalued.
Does Shandong Weigao Group Medical Polymer Co Ltd Class H pay dividends?
Shandong Weigao Group Medical Polymer Co Ltd Class H pays a Semiannually dividend of HK$0.1 which represents an annual dividend yield of 5.31%. See more information on Shandong Weigao Group Medical Polymer Co Ltd Class H dividends here
What is Shandong Weigao Group Medical Polymer Co Ltd Class H’s EPS estimate?
Shandong Weigao Group Medical Polymer Co Ltd Class H’s EPS estimate is 0.15.
How many shares outstanding does Shandong Weigao Group Medical Polymer Co Ltd Class H have?
Shandong Weigao Group Medical Polymer Co Ltd Class H has 4,522,332,500 shares outstanding.
What happened to Shandong Weigao Group Medical Polymer Co Ltd Class H’s price movement after its last earnings report?
Shandong Weigao Group Medical Polymer Co Ltd Class H reported an EPS of HK$0.198 in its last earnings report. Following the earnings report the stock price went up 1.163%.
Which hedge fund is a major shareholder of Shandong Weigao Group Medical Polymer Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:1066
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shandong Weigao Group Medical Polymer Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.60%
12-Months-Change
Fundamentals
Return on Equity
5.31%
Trailing 12-Months
Asset Growth
3.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shandong Weigao Group Medical Polymer Co Ltd Class H
Shandong Weigao Group Medical Polymer Company Limited, founded in 2000 and situated in Weihai, People's Republic of China, specializes in the research, development, production, and distribution of disposable medical devices across mainland China. The company structures its extensive operations into several core divisions, including Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and other specialized segments. Its comprehensive product range covers a vast array of essential healthcare items. This includes devices for both vascular and non-vascular access, such as infusion sets, syringes, and specialized puncture needles, alongside various clinical collection kits. Shandong Weigao also provides solutions for wound care, offering sutures, healing dressings, cleaning products, and support devices for non-vascular catheters. In the realm of blood management, it supplies equipment for collection, storage, separation, and sterilization. The company is also a manufacturer of prefilled and pre-flush syringes, as well as instruments for blood collection and glucose monitoring. Its portfolio further extends to anesthesia consumables (general, local, and auxiliary), intensive care unit (ICU) equipment, and tools for both open and minimally invasive surgical procedures. Beyond disposables, the firm is a key producer of orthopedic devices, instruments for tumor and blood vessel interventions, and advanced medical components such as implantation materials and artificial organs. It also ventures into industrial manufacturing, producing medical-grade PVC granules, various plastic packaging materials, carton boxes, automated industrial equipment and parts, molds, and hemodialysis machines, encompassing Type I, Type II, and Type III medical devices. In addition to its manufacturing activities, Shandong Weigao offers a range of supporting services. These include finance leasing and factoring, wholesale distribution of Type I, surgical, and other disposable medical products. The company also provides asset management, enterprise consulting, management advisory, and comprehensive logistics and storage solutions, while actively exporting its products to international markets. Operating under recognized brands like Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing, the company serves a diverse clientele that includes hospitals, blood banks, various other medical facilities, and a broad network of distributors.
1066 Stock 12 Month Forecast
Average Price Target
HK$4.54
▲(30.32% Upside)
Technical Analysis
PW Medtech Group Ltd.
―
Modern Dental Group Limited
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
Angelalign Technology Inc.
―
OrbusNeich Medical Group Holdings Limited
―






